LPGO fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Lipigon Pharmaceuticals AB engages in the development of drugs for diseases caused by disruptions in the body's handling of lipids. It focuses on small molecules, gene therapy, and antisense for patients with lipid disorders and other cardiometabolic risk factors. Lipigon products include P1 lipisense, P3 dyslipidemia and P4 CAP. The company was founded by Stefan Kristoffer Nilsson on April 6, 2010 and is headquartered in Umeå, Sweden.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
LPGO has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company